- Home
- EBS vs KALV Comparison
EBS vs KALV Comparison
Compare EBS & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- KALV
- Stock Information
- Founded
- EBS 1998
- KALV N/A
- Country
- EBS United States
- KALV United States
- Employees
- EBS N/A
- KALV N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- KALV Health Care
- Exchange
- EBS Nasdaq
- KALV Nasdaq
- Market Cap
- EBS 459.6M
- KALV 418.1M
- IPO Year
- EBS 2006
- KALV N/A
- Fundamental
- Price
- EBS $8.09
- KALV $8.36
- Analyst Decision
- EBS Strong Buy
- KALV Strong Buy
- Analyst Count
- EBS 2
- KALV 6
- Target Price
- EBS $14.00
- KALV $26.25
- AVG Volume (30 Days)
- EBS 999.1K
- KALV 421.6K
- Earning Date
- EBS 11-06-2024
- KALV 12-31-2024
- Dividend Yield
- EBS N/A
- KALV N/A
- EPS Growth
- EBS N/A
- KALV N/A
- EPS
- EBS N/A
- KALV N/A
- Revenue
- EBS $1,125,500,000.00
- KALV N/A
- Revenue This Year
- EBS $6.64
- KALV N/A
- Revenue Next Year
- EBS $7.95
- KALV N/A
- P/E Ratio
- EBS N/A
- KALV N/A
- Revenue Growth
- EBS 2.05
- KALV N/A
- 52 Week Low
- EBS $1.42
- KALV $7.98
- 52 Week High
- EBS $15.10
- KALV $16.88
- Technical
- Relative Strength Index (RSI)
- EBS 39.08
- KALV 36.75
- Support Level
- EBS $8.35
- KALV $8.48
- Resistance Level
- EBS $8.86
- KALV $9.30
- Average True Range (ATR)
- EBS 0.50
- KALV 0.65
- MACD
- EBS -0.11
- KALV -0.06
- Stochastic Oscillator
- EBS 17.58
- KALV 17.12
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.